Skip to main content
. Author manuscript; available in PMC: 2024 May 12.
Published in final edited form as: Nat Biomed Eng. 2023 Nov 27;8(4):479–494. doi: 10.1038/s41551-023-01134-x

Extended Data Fig. 2 |. Improved iPSC-CM maturation by hormone and fatty acid supplementation.

Extended Data Fig. 2 |

Treatment of human iPSC-CMs (SCVI-273) with a maturation media containing triiodothyronine (10 nM), dexamethasone (1 μM), oleic acid (30 μM), and palmitic acid (80 μM) for 6 days promoted the maturation of iPSC-CMs. a, qPCR analysis of maturation markers in iPSC-CMs with or without the maturation treatment. n = 3 technical replicates. Unpaired Student’s t-test. b, Western blot analysis of OXPHOS proteins in EHTs with or without the maturation treatment, including NDUFB8, SDHB, ubiquinol-cytochrome c reductase core protein 2 (UQCRC2), MTCO2, and ATP5A. n = 4 EHTs per group. Unpaired Student’s t-test. c, Measurement of oxygen consumption rate (OCR) of iPSC-CMs with or without the maturation treatment. n = 17 wells. 10,000 cells/well. Two-tailed Mann–Whitney test. d, Analysis of calcium handling using Fluo-4 dye in iPSC-CMs with or without the maturation treatment. n = 31 immature cells and n = 30 mature cells. Two-tailed Mann–Whitney test. e, Contractility analysis of EHTs with or without the maturation treatment. n = 8 EHTs per group. Two-tailed Mann–Whitney test. For a, b, and e, data were normalized against the untreated cells or EHTs. Data are displayed as mean ± s.e.m.